Organogenesis Holdings Inc.

NasdaqCM:ORGO 株式レポート

時価総額:US$326.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Organogenesis Holdings 過去の業績

過去 基準チェック /26

Organogenesis Holdingsは、平均年間39.7%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間15.5% 14%収益成長率で 成長しています。 Organogenesis Holdingsの自己資本利益率は2.1%であり、純利益率は1.3%です。

主要情報

39.7%

収益成長率

45.3%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率14.0%
株主資本利益率2.1%
ネット・マージン1.3%
前回の決算情報31 Mar 2024

最近の業績更新

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

収支内訳

Organogenesis Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:ORGO 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 24435626646
31 Dec 23433526644
30 Sep 234491327744
30 Jun 234571028743
31 Mar 234611329042
31 Dec 224511628240
30 Sep 224635927337
30 Jun 224607125936
31 Mar 224628325433
31 Dec 214679424931
30 Sep 214466223629
30 Jun 214336922624
31 Mar 213794320921
31 Dec 203381720320
30 Sep 20306-520317
30 Jun 20270-3720118
31 Mar 20266-4220317
31 Dec 19261-3920015
30 Sep 19250-4619214
30 Jun 19236-4818113
31 Mar 19215-5816811
31 Dec 18193-6515811
30 Sep 18183-6015010
30 Jun 18184-5214710
31 Mar 18187-3214210
31 Dec 17199-91349
31 Dec 16139-17936
31 Dec 1599-24744

質の高い収益: ORGOは 高品質の収益 を持っています。

利益率の向上: ORGOの現在の純利益率 (1.3%)は、昨年(2.9%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ORGO過去 5 年間で収益を上げており、収益は年間39.7%増加しています。

成長の加速: ORGOは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: ORGOは過去 1 年間で収益成長率がマイナス ( -56.9% ) となったため、 Biotechs業界平均 ( -14.4% ) と比較することが困難です。


株主資本利益率

高いROE: ORGOの 自己資本利益率 ( 2.1% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘